BPC-157 and TB-500 Anti-Doping Status in Sports
Peptide Doping and Detection
2 separate WADA categories
BPC-157 and TB-500 are prohibited under different sections of the WADA Prohibited List. BPC-157 falls under S0 (Non-Approved Substances) since 2022. TB-500 falls under S2 (Peptide Hormones and Growth Factors) since 2018.
WADA Prohibited List, 2026 Edition
WADA Prohibited List, 2026 Edition
View as imageBPC-157 and TB-500 are two of the most discussed peptides in sports recovery circles. Both are prohibited by the World Anti-Doping Agency (WADA), but under different categories, with different histories, and for different reasons. Athletes subject to drug testing by WADA, USADA, the NCAA, or any WADA-compliant organization cannot use either peptide at any time, whether in-competition or out-of-competition. Understanding exactly how and why each peptide is banned, and how testing laboratories detect them, is essential context for the broader landscape of peptide doping detection.
This article covers the regulatory classification, detection science, and practical consequences for athletes considering or already using these peptides.
Key Takeaways
- BPC-157 was added to the WADA Prohibited List in January 2022 under S0 (Non-Approved Substances), banned at all times (WADA, 2022)
- TB-500 (thymosin beta-4 derivative) has been prohibited since 2018 under S2.3 (Growth Factors and Growth Factor Modulators), banned at all times (WADA, 2018)
- BPC-157 metabolites are detectable in urine for 4-5 days with limits of detection as low as 0.01 ng/mL (Tian et al., Molecules, 2023)
- No Therapeutic Use Exemption (TUE) is available for BPC-157 because it is not approved for human use in any country
- TB-500 gained prominence in anti-doping after Australian horse racing doping scandals led to increased regulatory attention (Ho et al., J Chromatogr A, 2012)
- The NCAA specifically lists BPC-157 in its banned substance handbook, removing any ambiguity for collegiate athletes
What These Peptides Are and Why Athletes Use Them
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a segment of human gastric juice protein. In animal studies, it has demonstrated effects on wound healing, bone repair, and tissue protection across dozens of studies dating back to the 1990s.[1] Sebecic et al. (1999) reported that BPC-157 accelerated segmental bone defect healing in rabbits, showing osteogenic properties that attracted interest from athletes dealing with fractures and stress injuries.[2]
TB-500 is a synthetic peptide corresponding to the active region (amino acids 17-23) of thymosin beta-4 (Tβ4), a 43-amino-acid protein found naturally in nearly all human cells. Thymosin beta-4 plays roles in cell migration, blood vessel formation, and tissue repair. In animal models, it has been investigated for tendon tissue engineering and cardiac remodeling.[3][4]
Neither peptide has been approved for human therapeutic use by the FDA, EMA, or any other regulatory authority. No completed human clinical trials have established safety or efficacy for either compound. Athletes using them are consuming unapproved substances with unknown long-term effects in humans. For a broader overview of BPC-157 research and its regulatory status with the FDA, see the dedicated articles.
BPC-157: S0 Non-Approved Substances (Banned Since 2022)
BPC-157 was added to the WADA Prohibited List effective January 1, 2022, under Section S0: Non-Approved Substances. This category covers any pharmacological substance not addressed by other sections of the list that has no current regulatory approval for human therapeutic use.
What S0 means in practice
S0 is the broadest category on the WADA Prohibited List. It functions as a catch-all for substances that are not approved by any governmental regulatory health authority for human therapeutic use. BPC-157 qualifies because it has never completed a Phase III clinical trial, never received regulatory approval from the FDA or any equivalent body, and remains classified by the FDA under Category 2 (substances that cannot be compounded as they have insufficient safety and efficacy data for human use).
The S0 classification means:
- Prohibited at all times (in-competition and out-of-competition)
- No Therapeutic Use Exemption (TUE) is available, because there is no approved therapeutic indication
- Any positive test results in a doping violation regardless of intent
Why 2022 and not earlier?
Before 2022, BPC-157 technically fell under S0 by default (any non-approved substance is prohibited), but it was not explicitly named on the list. The 2022 update added it by name following increased detection of the peptide in athlete samples and growing awareness of its use in sports. The U.S. Anti-Doping Agency (USADA) specifically flagged BPC-157 as creating risk for athletes, noting that the substance is found in health and wellness products sometimes marketed without disclosing its prohibited status.
TB-500: S2 Peptide Hormones and Growth Factors (Banned Since 2018)
TB-500 falls under a different and more specific prohibition. WADA lists "Thymosin-β4 and its derivatives (e.g. TB-500)" under Section S2.3: Growth Factors and Growth Factor Modulators. This category covers substances that affect muscle, tendon, or ligament protein synthesis/degradation, vascularization, energy utilization, regenerative capacity, or fiber type switching.
The S2 classification
Unlike BPC-157's S0 catch-all, TB-500's S2 placement reflects WADA's determination that the peptide has specific performance-enhancing properties related to tissue growth and repair. The S2 category includes better-known substances like growth hormone, IGF-1, and mechano growth factors. For the full scope of growth hormone secretagogues and why WADA bans them, see the dedicated article.
Key implications:
- Prohibited at all times (in-competition and out-of-competition)
- Classified as a Specified Substance, meaning reduced sanctions may apply if an athlete can demonstrate no intent to enhance performance
- TUE applications are theoretically possible but practically unlikely for TB-500 given the lack of approved therapeutic indications
The horse racing connection
TB-500's path onto the WADA list was partly driven by doping scandals in Australian horse racing. Trainers were using TB-500 to accelerate equine injury recovery, and when racing authorities developed detection methods and cracked down on its use, the peptide's profile was raised significantly. Ho et al. (2012) published one of the earliest validated detection methods for TB-500, originally developed for equine urine and plasma testing.[5] More recently, Delcourt et al. (2025) developed population-level strategies for detecting thymosin beta-4 misuse in equine doping controls.[6] The analytical methods developed for horse racing were subsequently adapted for human anti-doping programs.
How Testing Laboratories Detect These Peptides
Detection of small peptides like BPC-157 and TB-500 has advanced substantially over the past decade. Modern anti-doping laboratories use liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS) to identify these compounds and their metabolites in biological samples.[7]
BPC-157 detection
Cox et al. (2017) published the first validated detection and in vitro metabolism study for BPC-157 in a doping control context. The method identified BPC-157 in confiscated samples and characterized its metabolic breakdown products, establishing a detection limit of 0.1 ng/mL with good linearity (r² = 0.998).[8]
Tian et al. (2023) advanced detection capabilities using a stable isotope labeling-based nontargeted strategy with UHPLC-HRMS to map BPC-157's complete in vitro metabolic profile. They identified nine metabolites: one from a novel metabolic pathway and eight from conventional amide-bond breaking pathways. The validated detection limits ranged from 0.01 to 0.11 ng/mL, well below WADA's 2 ng/mL minimum required performance level for peptide compounds.[9]
BPC-157 metabolites remained stable and detectable in urine for 4-5 days after administration. This detection window, combined with the sensitivity of current assays, means that athletes cannot reliably "clear" the peptide from their system before a test.
TB-500 detection
TB-500 detection presents a different analytical challenge because thymosin beta-4 is an endogenous protein, naturally present in blood and tissues. Testing laboratories must distinguish between naturally occurring thymosin beta-4 and exogenously administered TB-500 or elevated levels resulting from injection. Chang et al. (2021) developed methods using LC-HRMS with parallel reaction monitoring that can detect small peptides including TB-500 fragments in human urine at low concentrations.[10]
The broader peptide detection landscape
Judak et al. (2021) reviewed a decade of progress in small peptide doping control, noting that analytical sensitivity has improved by orders of magnitude since the early 2010s. Methods that once required milliliter volumes of sample can now detect peptides from dried blood spots, and the shift to high-resolution accurate mass spectrometry has enabled simultaneous screening for dozens of peptide targets in a single analytical run.[7]
Gomez-Guerrero et al. (2022) described how synthetic reference peptides serve as essential calibration tools for anti-doping laboratories, enabling accurate quantification and metabolite identification across the growing list of prohibited peptides.[11] For a detailed look at how all these testing methods work across peptide categories, see the pillar article.
What Happens If an Athlete Tests Positive
The consequences of a positive test for BPC-157 or TB-500 depend on the governing body, the athlete's history, and the circumstances.
First offense under WADA Code
For a first anti-doping rule violation involving a prohibited substance, the standard sanction is a four-year suspension from competition. This can be reduced to two years if the athlete can demonstrate that the violation was not intentional.
TB-500 as a Specified Substance
TB-500 is classified as a Specified Substance under S2, meaning an athlete who tests positive may be able to argue for a reduced sanction if they can demonstrate how the substance entered their body and that there was no intent to enhance performance. BPC-157's S0 classification does not carry the same Specified Substance designation, though the circumstances of each case are evaluated individually.
No TUE path for either peptide
Neither BPC-157 nor TB-500 has an approved therapeutic indication. Without an approved medical use, there is no basis for granting a Therapeutic Use Exemption. An athlete with a legitimate injury cannot obtain a TUE for either peptide regardless of medical need, because no regulatory authority has determined these substances are safe and effective for any condition.
NCAA and other bodies
The NCAA specifically lists BPC-157 in its banned substance handbook. Collegiate athletes are subject to testing and sanctions independent of WADA, and NCAA sanctions can include loss of eligibility and scholarship consequences. Professional sports leagues (NFL, NBA, MLB, UFC) that follow WADA or USADA protocols enforce the same prohibitions. The complete WADA prohibited peptide list covers every banned peptide across all categories. Separately, GLP-1 agonists occupy a more nuanced position in the anti-doping landscape.
The Gap Between Online Claims and Regulatory Reality
BPC-157 and TB-500 are widely available from research chemical suppliers and compounding pharmacies, and online communities frequently discuss their use for injury recovery. This accessibility creates a dangerous disconnect for athletes.
The FDA classified BPC-157 as a Category 2 substance in 2024, meaning it cannot be legally compounded for human use in the United States. Despite this, products containing BPC-157 continue to be sold. Athletes who purchase these products risk not only an anti-doping violation but also exposure to contaminants, mislabeled dosages, and unknown impurities, problems documented across the gray-market peptide supply chain.
TB-500 occupies a similar regulatory gray area. While thymosin beta-4 has been investigated in clinical trials for cardiac repair and wound healing, TB-500 specifically (the synthetic fragment) has not undergone regulatory review. The distinction between the full-length protein and the synthetic fragment matters for regulatory purposes but is often ignored in marketing.
The fundamental problem for athletes is that "available for purchase" does not mean "legal to use in sport" or "safe for human consumption." Both peptides remain unresolved in the regulatory landscape, and athletes bear the full consequences of positive tests regardless of the ease of acquisition.
Comparison Table: BPC-157 vs. TB-500 Anti-Doping Status
| Category | BPC-157 | TB-500 |
|---|---|---|
| WADA Section | S0 (Non-Approved Substances) | S2.3 (Growth Factors) |
| Prohibited Since | January 2022 | 2018 |
| When Prohibited | At all times | At all times |
| Specified Substance | No | Yes |
| TUE Available | No | No (no approved indication) |
| FDA Status | Category 2 (cannot compound) | Not approved |
| Detection Window | 4-5 days (urine metabolites) | Variable (endogenous baseline complicates testing) |
| Detection Sensitivity | 0.01-0.11 ng/mL | Sub-ng/mL via LC-HRMS |
The Bottom Line
BPC-157 and TB-500 are both prohibited by WADA but under different classifications. BPC-157 falls under S0 (Non-Approved Substances) since 2022 because it has never been approved for human use by any regulatory authority. TB-500 falls under S2.3 (Growth Factors) since 2018 based on its tissue repair properties. Modern LC-HRMS methods can detect BPC-157 metabolites at 0.01 ng/mL in urine, and the detection window extends 4-5 days. Neither peptide qualifies for a Therapeutic Use Exemption. Athletes subject to any WADA-compliant testing program risk four-year suspensions for positive tests.